About this compound
Spiropiperidine derivative acting as selective agonist of the ghrelin receptor. Increases GH and IGF-1 levels in published human pharmacology studies.
Specification
| Compound | MK-677 |
| Class | Orally-available GHS-R1a agonist (small molecule) |
| Molecular weight | 528.66 g/mol |
| Form | Lyophilized powder |
| Purity | >99% HPLC — verified by two independent labs |
| Storage | Lyophilized: 2–8°C protected from light. Reconstituted: −20°C, use within 28 days. Avoid freeze–thaw cycles. |
Reported research areas
- Long-term GH/IGF-1 elevation studies
- Animal bone-turnover models
Selected references
- Murphy et al. 1998 — PMID 9627287
Independent verification
Every batch is tested by Janoshik Analytical (Czech Republic, HPLC + MS) and Aethos Bioanalytics (US, independent HPLC + LAL endotoxin where applicable). Both Certificates of Analysis are published on this product page — never edited, never curated. If the two labs disagree on purity by more than 0.5%, the entire lot is destroyed.
Disclaimer
FOR RESEARCH USE ONLY. Not for human consumption. No diagnostic or therapeutic use. By purchasing this product, you affirm you are using it strictly for laboratory research purposes in a controlled setting.
Reviews
There are no reviews yet.